RNA-based therapy for osteogenesis.
Gene therapy
Osteogenesis
Osteoporosis
Protein replacement
RNA interference
mRNA
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
05 Oct 2019
05 Oct 2019
Historique:
received:
30
04
2019
revised:
02
08
2019
accepted:
03
08
2019
pubmed:
9
8
2019
medline:
28
1
2020
entrez:
9
8
2019
Statut:
ppublish
Résumé
Nucleic acid-based therapy has shown great promise in accelerating bone regeneration as well as other diseases. Nucleic acids used in gene therapy mainly are either plasmid DNA (pDNA) or RNAs. Although pDNA therapy has been extensively studied for decades with encouraging preclinical and clinical results, side effects, and low efficiency associated with nuclear trafficking are hard to bypass. Unlike pDNA, RNAs (mRNA, siRNA, miRNA) exert their function in the cytoplasm, thereby being more efficient in hard-to-transfect cells such as primary osteoblasts. RNA interference-based gene silencing represents a negative regulation which knockdown the expression of antagonists that impair osteogenesis process. In contrary, mRNA therapy for osteogenesis represents a positive regulation which delivers mRNA encoding growth factors to accelerate bone regeneration. This review presents a comprehensive summary of the mRNA and siRNA-based therapies and the targets for bone regeneration in case of bone defect and osteoporosis.
Identifiants
pubmed: 31394184
pii: S0378-5173(19)30639-8
doi: 10.1016/j.ijpharm.2019.118594
pii:
doi:
Substances chimiques
RNA, Messenger
0
RNA, Small Interfering
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
118594Informations de copyright
Copyright © 2019. Published by Elsevier B.V.